If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16 th Floor New York NY  10036  682-3025 593-4771 stockinfo@weisslawllp.com DSP Group, Inc. WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations ...

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16 th Floor
New York , NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

DSP Group, Inc. (NASDAQ: DSPG)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of DSP Group, Inc. (NASDAQ: DSPG) in connection with the proposed acquisition of the company by Synaptics Incorporated. Under the terms of the merger agreement, the company's shareholders will receive $22.00 per share in cash for each share of DSPG common stock that they hold. If you own DSPG shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/dspg

ADTRAN, Inc. (NASDAQ: ADTN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ADTRAN, Inc. (NASDAQ: ADTN) in connection with the proposed stock-for-stock merger of the company with ADVA ("ADVA"). ADTN and ADVA will combine under a new holding company, which will be renamed ADTRAN Holdings, Inc. following the closing. Under the terms of the merger agreement, each ADVA share will be exchanged for 0.8244 shares of the new holding company. ADTN shares will be exchanged for shares in the new holding company on a one-for-one basis. At the closing, ADTN shareholders will own approximately 54% of the equity of the combined company and ADVA shareholders will own approximately 46%. If you own ATDN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/adtn

Trillium Therapeutics Inc. (NASDAQ: TRIL)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Trillium Therapeutics Inc. (NASDAQ: TRIL) in connection with the proposed acquisition of the company by Pfizer Inc. Under the terms of the merger agreement, the company's shareholders will receive $18.50 per share in cash for each share of TRIL common stock that they hold. If you own TRIL shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/tril

Veoneer, Inc. (NYSE: VNE)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Veoneer, Inc. (NYSE: VNE) in connection with the company's proposed acquisition by Magna International Inc. Pursuant to the merger agreement, the company's shareholders will receive $31.25 per share in cash for each share of VNE common stock that they hold. If you own VNE shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/vne

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-dspg-adtn-tril-and-vne-shareholders-about-its-ongoing-investigations-301381170.html

SOURCE WeissLaw LLP

News Provided by PR Newswire via QuoteMedia

Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis

U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process

Keep reading... Show less

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, LSPD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits

Bristol-Myers Squibb Company (NYSE:BMY)

Keep reading... Show less
8,000 plus Attend Boosh Sponsored Planted Expo in Vancouver

8,000 plus Attend Boosh Sponsored Planted Expo in Vancouver

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is proud to announce that over 8,000 consumers and investors visited the largest plant-based expo in Canada; Planted-Expo at which Boosh was the presenting sponsor. At the event Boosh proudly introduced its brand-new shelf stable line of Boosh Mac & Cheeze; Nacho and Better Cheddar to rave reviews, and provided samples to consumers of Boosh's favourite foods including Shephard's Pie, and recently acquired brands such as Salt Spring Harvest pate and Pulse Specialty Kitchen plant-based cheeses.

Keep reading... Show less

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, CTXS, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Keep reading... Show less

Amgen To Present At The 2021 Evercore ISI Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday Nov. 30, 2021. Rob Lenz M.D., Ph.D., senior vice president of Global Development at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

Keep reading... Show less

Top News

Related News